<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254187</url>
  </required_header>
  <id_info>
    <org_study_id>1184.17</org_study_id>
    <nct_id>NCT02254187</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male Volunteers</brief_title>
  <official_title>A Randomised, Open-label Three-way Crossover Study to Evaluate the Pharmacokinetics of Salmeterol After Inhalation of a 25 μg and 50 μg Single Dose (Inhalation Powder, Hard PE Capsule for HandiHaler®2) and a 50 μg Single Dose (Serevent® Diskus®) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate if the systemic drug exposure of at least 25 μg&#xD;
      and perhaps 50 μg salmeterol presented as inhalation powder in PE capsules and administered&#xD;
      via HandiHaler® 2 does not exceed that of 50 μg Serevent® Diskus® and to investigate safety&#xD;
      and tolerability of salmeterol presented as inhalation powder in PE capsules and administered&#xD;
      via HandiHaler® 2&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of salmeterol in blood plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 8 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of salmeterol in blood plasma)</measure>
    <time_frame>up to 8 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of salmeterol in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt1-t2 (area under the concentration time curve of salmeterol in plasma over the time interval t1 to t2)</measure>
    <time_frame>up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of salmeterol in plasma)</measure>
    <time_frame>up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ (terminal half-life of salmeterol in plasma)</measure>
    <time_frame>up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTih (mean residence time of salmeterol in the body after inhalational administration)</measure>
    <time_frame>up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of salmeterol in the plasma after extravascular administration)</measure>
    <time_frame>up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase (λz) following an extravascular dose)</measure>
    <time_frame>up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 14 days following the last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>up to 14 days following the last drug administration</time_frame>
    <description>Blood Pressure, Pulse Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in 12-lead ECG parameters</measure>
    <time_frame>up to 14 days following the last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 14 days following the last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>14 days following the last drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Salmeterol capsule via Handihaler - low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol capsule via Handihaler - high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol via Serevent® Diskus®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol capsule - low</intervention_name>
    <arm_group_label>Salmeterol capsule via Handihaler - low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol capsule - high</intervention_name>
    <arm_group_label>Salmeterol capsule via Handihaler - high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol via Serevent® Diskus®</intervention_name>
    <arm_group_label>Salmeterol via Serevent® Diskus®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male based upon a complete medical history, including the physical&#xD;
             examination, regarding vital signs ((Blood Pressure (BP), Pulse Rate (PR)), 12-lead&#xD;
             ECG measurement, and clinical laboratory tests. There is no finding deviating from&#xD;
             normal and of clinical relevance. There is no evidence of a clinically relevant&#xD;
             concomitant disease.&#xD;
&#xD;
          2. Age ≥21 and ≤50 years&#xD;
&#xD;
          3. BMI ≥18.5 and &lt;30 kg/m2 (Body Mass Index)&#xD;
&#xD;
          4. Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with Good Clinical Practice (GCP) and the local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any finding of the medical examination (including BP, PR, and ECG measurements)&#xD;
             deviating from normal and of clinical relevance&#xD;
&#xD;
          2. Evidence of a clinically relevant concomitant disease&#xD;
&#xD;
          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or&#xD;
             neurological disorders&#xD;
&#xD;
          5. History of relevant orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
          6. Chronic or relevant acute infections&#xD;
&#xD;
          7. History of relevant allergy/hypersensitivity (including allergy to the drug or its&#xD;
             excipients) as judged clinically relevant by the investigator&#xD;
&#xD;
          8. Intake of drugs with a long half-life (&gt;24 hours) within at least 1 month or less than&#xD;
             10 half-lives of the respective drug prior to randomization&#xD;
&#xD;
          9. Use of drugs which might reasonably influence the results of the trial based on the&#xD;
             knowledge at the time of protocol preparation within 10 days prior to randomization&#xD;
&#xD;
         10. Participation in another trial with an investigational drug within 2 months prior to&#xD;
             randomization&#xD;
&#xD;
         11. Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day)&#xD;
&#xD;
         12. Inability to refrain from smoking on trial days as judged by the investigator&#xD;
&#xD;
         13. Alcohol abuse (more than 60 g alcohol a day)&#xD;
&#xD;
         14. Drug abuse&#xD;
&#xD;
         15. Blood donation (more than 100 mL blood within 4 weeks prior to randomization or during&#xD;
             the trial)&#xD;
&#xD;
         16. Excessive physical activities within 1 week prior to randomization or during the trial&#xD;
&#xD;
         17. Any laboratory value outside the reference range that is of clinical relevance&#xD;
&#xD;
         18. Inability to comply with dietary regimen of the study centre&#xD;
&#xD;
             The following exclusion criteria are specific for this study due to the known class&#xD;
             side effect profile of ß2-mimetics:&#xD;
&#xD;
         19. Asthma or history of pulmonary hyperreactivity&#xD;
&#xD;
         20. Hyperthyrosis&#xD;
&#xD;
         21. Allergic rhinitis in need of treatment&#xD;
&#xD;
         22. Clinically relevant cardiac arrhythmia&#xD;
&#xD;
         23. Paroxysmal tachycardia (&gt;100 beats per minute)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

